Show simple item record

dc.contributor.authorSánchez-Maldonado, J M
dc.contributor.authorCampa, D
dc.contributor.authorSpringer, J
dc.contributor.authorBadiola, J
dc.contributor.authorNiazi, Y
dc.contributor.authorMoñiz-Díez, A
dc.contributor.authorHernández-Mohedo, F
dc.contributor.authorGonzález-Sierra, P
dc.contributor.authorTer Horst, R
dc.contributor.authorMacauda, A
dc.contributor.authorBrezina, S
dc.contributor.authorCunha, C
dc.contributor.authorLackner, M
dc.contributor.authorLópez-Nevot, M A
dc.contributor.authorFianchi, L
dc.contributor.authorPagano, L
dc.contributor.authorLópez-Fernández, E
dc.contributor.authorPotenza, L
dc.contributor.authorLuppi, M
dc.contributor.authorMoratalla, L
dc.contributor.authorRodríguez-Sevilla, J J
dc.contributor.authorFonseca, J E
dc.contributor.authorTormo, M
dc.contributor.authorSolano, C
dc.contributor.authorClavero, E
dc.contributor.authorRomero, A
dc.contributor.authorLi, Y
dc.contributor.authorLass-Flörl, C
dc.contributor.authorEinsele, H
dc.contributor.authorVazquez, L
dc.contributor.authorLoeffler, J
dc.contributor.authorHemminki, K
dc.contributor.authorCarvalho, A
dc.contributor.authorNetea, M G
dc.contributor.authorGsur, A
dc.contributor.authorDumontet, C
dc.contributor.authorCanzian, F
dc.contributor.authorFörsti, A
dc.contributor.authorJurado, M
dc.contributor.authorSainz, J
dc.date.accessioned2020-11-11T14:57:06Z
dc.date.available2020-11-11T14:57:06Z
dc.date.issued2020-07-16
dc.identifier.citationBlood Cancer J. 2020 Jul 16;10(7):75. doi: 10.1038/s41408-020-00341-y.en_US
dc.identifier.pmid32678078
dc.identifier.doi10.1038/s41408-020-00341-y
dc.identifier.urihttp://hdl.handle.net/10033/622576
dc.description.abstractThe purpose of this study was to conduct a two-stage case control association study including 654 acute myeloid leukaemia (AML) patients and 3477 controls ascertained through the NuCLEAR consortium to evaluate the effect of 27 immune-related single nucleotide polymorphisms (SNPs) on AML risk. In a pooled analysis of cohort studies, we found that carriers of the IL13rs1295686A/A genotype had an increased risk of AML (PCorr = 0.0144) whereas carriers of the VEGFArs25648T allele had a decreased risk of developing the disease (PCorr = 0.00086). In addition, we found an association of the IL8rs2227307 SNP with a decreased risk of developing AML that remained marginally significant after multiple testing (PCorr = 0.072). Functional experiments suggested that the effect of the IL13rs1295686 SNP on AML risk might be explained by its role in regulating IL1Ra secretion that modulates AML blast proliferation. Likewise, the protective effect of the IL8rs2227307 SNP might be mediated by TLR2-mediated immune responses that affect AML blast viability, proliferation and chemorresistance. Despite the potential interest of these results, additional functional studies are still warranted to unravel the mechanisms by which these variants modulate the risk of AML. These findings suggested that IL13, VEGFA and IL8 SNPs play a role in modulating AML risk.en_US
dc.language.isoenen_US
dc.publisherSpringer Natureen_US
dc.rightsAttribution-NonCommercial-ShareAlike 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.titleHost immune genetic variations influence the risk of developing acute myeloid leukaemia: results from the NuCLEAR consortium.en_US
dc.typeArticleen_US
dc.identifier.eissn2044-5385
dc.contributor.departmentCiiM, Zentrum für individualisierte Infektionsmedizin, Feodor-Lynen-Str.7, 30625 Hannover.en_US
dc.identifier.journalBlood cancer journalen_US
dc.source.volume10
dc.source.issue7
dc.source.beginpage75
dc.source.endpage
refterms.dateFOA2020-11-11T14:57:07Z
dc.source.journaltitleBlood cancer journal
dc.source.countryUnited States


Files in this item

Thumbnail
Name:
Sánchez-Maldonado et al.pdf
Size:
656.8Kb
Format:
PDF
Description:
Open Access publication

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International